About Zealand
About us
Disease focus
Strategy
History
Corporate presentation
and factsheet
Corporate Management
Board of Directors
Corporate governance
Audit Committee
Remuneration and Compensation Committee
Nomination Committee
Corporate social responsibility
Videos about Zealand
R&D
Our focus
Product pipeline
Orphan drug designation
Glepaglutide (SBS)
Dasiglucagon (rescue)
Dasiglucagon (pump)
Dasiglucagon (CHI)
GLP-1/glucagon dual-acting agonist
Long-acting amylin analog
Inlicensing
What are peptides?
Publications
Scientific Advisory Board
Investor
Investor relations
Stock information
Shareholder portal
Financial calendar
Financial reports
Events
Capital Market Days 2018
Annual General Meeting 2018
Conference calls
SEC filings
Analyst Coverage
Media
Zealand news
Media inquiry
Downloads
Careers
Zealand as a workplace
Meet us
Positions
Unsolicited applications
Personal data in the recruitment process
Contact
About Zealand
About us
Disease focus
Strategy
History
Corporate presentation
and factsheet
Corporate Management
Board of Directors
Corporate governance
Audit Committee
Remuneration and Compensation Committee
Nomination Committee
Corporate social responsibility
Videos about Zealand
R&D
Our focus
Product pipeline
Orphan drug designation
Glepaglutide (SBS)
Dasiglucagon (rescue)
Dasiglucagon (pump)
Dasiglucagon (CHI)
GLP-1/glucagon dual-acting agonist
Long-acting amylin analog
Inlicensing
What are peptides?
Publications
Scientific Advisory Board
Investor
Investor relations
Stock information
Shareholder portal
Financial calendar
Financial reports
Events
Capital Market Days 2018
Annual General Meeting 2018
Conference calls
SEC filings
Analyst Coverage
Media
Zealand news
Media inquiry
Downloads
Careers
Zealand as a workplace
Meet us
Positions
Unsolicited applications
Personal data in the recruitment process
Contact
Media
Zealand news
Media inquiry
Downloads
Contact information
Alette Pramming
Communications
Phone: +45 53 73 57 50
apr@zealandpharma.com
